Tobacco and Public Health - TCSC Indonesia

146
PHARMACOLOGY OF NICOTINE ADDICTION
Slade, J. (1995). Are tobacco product drugs? Evidence from U.S. tobacco. Tobacco Control, 4(1), 1–2.
Slade, J., Bero, L. A., Hanauer, P., Barnes, D. E., and Glantz, S. A. (1995). Nicotine and addiction.
The Brown and Williamson documents. Journal of the American Medical Association,
274 (3), 225–33.
Slade, J., and Henningfield, J. E. (1998). Tobacco product regulation: context and issues. Food and
Drug Law Journal, 53 (Suppl.), 43–74.
Soria, R., Stapleton, J. M., Gilson, S. F., Sampson-Cone, A., Henningfield, J. E., and London, E. D.
(1996). Subjective and cardiovascular effects of intravenous nicotine in smokers and
non-smokers. Psychopharmacology (Berl), 128 (3), 221–6.
Stitzer, M. L., and De Wit, H. (1998). Abuse liability of nicotine. In: Nicotine safety and toxicity (ed.
N.L. Benowitz), pp. 119–31. Oxford University Press, NY.
Stolerman, I. P., Goldfarb, T., Fink, R., and Jarvik, M. E. (1973). Influencing cigarette smoking with
nicotine antagonists. Psychopharmacologia, 28, 217–59.
Swedberg, M. D. B., Henningfield, J. E., and Goldberg, S. R. (1990). Nicotine dependency:
animal studies. In: Nicotine psychopharmacology: molecular, cellular, and behavioural aspects
(ed. S. Wonnacott, M. A. H. Russell, and I. P. Stolerman), pp. 38–76. Oxford University Press.
Taylor, P. (1996). Agents acting at the neuromuscular junction and autonomic ganglia. In: Goodman
and Gilman’s The Pharmacological basis of therapeutics (ed. J.G. Hardman, L.E. Limbrid, P.B.
Molinoff, R.W. Ruddon, and A.G. Gilman, T.), pp. 177–97. McGraw-Hill, NY.
Tomar, S. L., and Henningfield, J. E. (1997). Review of the evidence that pH is a determinant of
nicotine dosage from oral use of smokeless tobacco. Tobacco Control, 6, 219–25.
Thun, M. J., and Burns, D. M. (2001). Health impact of ‘reduced yield’ cigarettes: a critical assessment
of the epidemiological evidence. Tobacco Control, 10 (Suppl 1), i4–i11.
Tyndale, R. F., and Sellers, E. M. (2001). Variable CYP2A6-mediated nicotine metabolism alters
smoking behavior and risk. Drug Metabolism and Disposition, 29(4 Pt 2), 548–52.
U.S. Department of Health and Human Services (1988). The health consequences of smoking: nicotine
addiction, a report of the Surgeon General.U.S. Government Printing Office, Washington, DC.
U.S. Department of Health and Human Services (1994). Preventing tobacco use among young people.
A report of the Surgeon General.U.S. Government Printing Office, Washington, DC.
U.S. Department of Health and Human Services (2000). Reducing tobacco use. A report of the Surgeon
General.U.S. Government Printing Office, Washington, DC.
U.S. Department of Health and Human Services (2001). Women and Smoking: a report of the Surgeon
General.U.S. Department of Health and Human Services, Public Health Service, Office of the
Surgeon General, Rockville, MD.
Vidal, C. (1996). Nicotinic receptors in the brain. Molecular biology, function, and therapeutics.
Molecular Chemistry and Neuropathology, 28 (1–3), 3–11
Vocci, F. J. (1989). The necessity and utility of abuse liability evaluations in human subjects: the FDA
perspective. In M.W. Fischman, and N.K. Mello (ed.), Testing for abuse liability of drugs in
humans. NIDA research monograph no. 92 (pp. 7–20). DHHS publication number (ADM)
89–1613. U.S. Department of Health and Human Services, Rockville, MD.
Volkow, N. D., Fowler, J. S., Ding, Y. S., Wang, G. J., and Gatley, S. J. (1999). Imaging the neurochemistry
of nicotine actions: studies with positron emission tomography. Nicotine and Tobacco
Research, 1 (Suppl 2), S127–S132
Wallace, B. C. (1989). Psychological and environmental determinants of relapse in crack cocaine
smokers. Journal of Substance Abuse Treatment, 6, 95–106.